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TARGETING DNA REPAIR IN METASTATIC CASTRATION-
RESISTANT PROSTATE CANCER (mCRPC): GENOMIC SCREENING 
FOR A CLINICAL TRIAL OF RUCAPARIB 
Alan Bryce M.D.*, Mitchell E. Gross M.D., Ph.D.*, Charles Redfern 
M.D.*, Nicholas Vogelzang M.D.*, Matthew Rettig M.D.*, Thomas 
Stanton M.D.*, Julie N. Graff M.D.*, Sandhya Srinivas M.D.*, Andrea 
Loehr Ph.D.*, Wassim Abida M.D., Ph.D.* 
Phoenix, AZ 
 (Presentation to be made by Dr. Alan Bryce)  
Objectives: The high prevalence of men with mCRPC carrying 
pathogenic mutations in DNA damage repair (DDR) genes may have 
implications for clinical treatment, as poly(ADP-ribose) polymerase 
(PARP) inhibitors, such as rucaparib, have shown preliminary evidence of 
activity in these patients. The ongoing phase 2 TRITON2 study 
(NCT02952534) is evaluating rucaparib in mCRPC patients harboring a 
deleterious germline or somatic mutation in BRCA1, BRCA2, ATM, or 
other DDR gene. Here we present results from genomic screening of 
tissue and plasma samples from mCRPC patients. 
Methods: Comprehensive genomic profiling was performed by 
Foundation Medicine, Inc., using FFPE tumor tissue and plasma 
circulating cell-free DNA (cfDNA) samples. These next-generation 
sequencing (NGS) assays detect germline and somatic genomic 
alterations (GAs), but do not distinguish between them. 
Results: By Jan 15, 2019, prostate or metastatic tumor tissue samples 
from 1050 mCRPC patients were processed. Sequencing was successful 
for 68% of prostate samples, 82% of soft-tissue metastatic samples, and 
57% of bone metastatic samples. In total, tissue sequencing results were 
obtained for 774 (74%) patients. GAs in BRCA1, BRCA2, or ATM were 
observed in 16.7% of patients’ tissue. In parallel, plasma from 654 mCRPC 
patients was collected and sequenced: 96% of plasma samples had 
sufficient cfDNA to obtain sequencing results, and sequencing success 
was independent of the location of metastases (visceral, nodal, or bone). 
GAs in BRCA1, BRCA2, or ATM were observed in 21.4% of patients’ 
plasma. There was high concordance between the alterations detected by 
the tissue and plasma assays. For example, in 86% of patients the plasma 
assay detected the same BRCA2 alteration present in tissue. 
Conclusions: Genomic profiling may help guide clinical decision-making 
for mCRPC patients. Tumor and plasma testing successfully identified 
patients with eligible somatic or germline GAs for enrollment into 
TRITON2. These data continue to support the utilization of plasma 
genomic testing, particularly in patients without a lesion that can be 
biopsied. 
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